BUY 1 GET 1 FREE – SELECT PRODUCTS, LIMITED TIME ONLY! Enjoy FREE SHIPPING on all Orders of $200 or more.

Sale!
NAD+-500MG

NAD+ – 500mg

SKU: PEP-NAD+-500MG
Original price was: $90.00.Current price is: $75.00.

    NAD+ – 500mg, Premium Lyophilized Peptide Powder, 99% Purity.

    BUY MORE & SAVE!

    Buy 5 – Get 5% discount
    Buy 10 or more – Get 10% discount
    Discount will automatically be applied at checkout

    NAD+ (Nicotinamide adenine dinucleotide) peptides are of growing interest in both clinical and preclinical research due to their roles in cellular metabolism, aging, and various diseases. NAD+ is a critical coenzyme in redox reactions and is involved in essential processes such as energy metabolism, DNA repair, and regulation of cellular stress responses. Below are some clinical and preclinical research use cases for NAD+ peptides:

    1. Aging and Age-Related Diseases

    • Preclinical: Research on NAD+ peptides focuses on their ability to restore NAD+ levels, which decline with age. Increasing NAD+ levels is hypothesized to slow down or reverse aspects of aging by enhancing mitochondrial function, DNA repair, and improving cellular metabolism.
    • Clinical: Clinical trials investigate NAD+ peptides as potential interventions for age-related conditions like neurodegeneration, muscle wasting, and cognitive decline. NAD+ supplementation or peptides may improve muscle function, mitochondrial health, and overall vitality in older adults.

    2. Neurodegenerative Diseases

    • Preclinical: NAD+ peptides are studied in animal models of neurodegenerative diseases like Alzheimer’s, Parkinson’s, and Huntington’s disease. They are thought to have neuroprotective effects, improving neuronal survival, enhancing neurogenesis, and reducing oxidative stress and inflammation.
    • Clinical: Early-stage clinical trials are exploring NAD+ precursors or peptides as potential treatments for diseases like Alzheimer’s and Parkinson’s. Researchers are investigating how boosting NAD+ levels could slow disease progression and improve cognitive function.

    3. Metabolic Disorders and Obesity

    • Preclinical: NAD+ plays a vital role in regulating metabolic pathways, including those that control glucose and lipid metabolism. Preclinical studies have shown that NAD+ peptides can improve insulin sensitivity, reduce obesity, and prevent diabetes-related complications.
    • Clinical: Clinical studies are assessing whether NAD+ peptide supplementation can help treat metabolic disorders, including obesity, Type 2 diabetes, and metabolic syndrome. Boosting NAD+ levels could improve insulin resistance, fat metabolism, and overall metabolic health.

    4. Cardiovascular Health

    • Preclinical: NAD+ peptides may enhance vascular function and protect against cardiovascular diseases. Preclinical research has explored how NAD+ impacts endothelial function, oxidative stress, and vascular remodeling, which are essential in heart disease.
    • Clinical: Clinical trials are investigating whether NAD+ peptides can reduce the risk of cardiovascular diseases such as atherosclerosis, hypertension, and heart failure. Some studies focus on improving blood vessel health and reducing the risk of age-related cardiovascular conditions.

    5. Cancer Therapy

    • Preclinical: NAD+ peptides are being evaluated for their potential to modulate the tumor microenvironment. Some studies suggest that increasing NAD+ could enhance the efficacy of chemotherapy and radiation by improving DNA repair mechanisms in normal cells and by enhancing the effects of cancer treatments on tumor cells.
    • Clinical: Clinical research is focused on evaluating whether NAD+ peptides could be used as adjuvants to standard cancer treatments, potentially improving therapeutic outcomes, reducing side effects, and promoting tumor regression.

    6. DNA Repair and Cellular Stress Response

    • Preclinical: NAD+ is critical for DNA repair through its role in activating enzymes like PARPs (Poly(ADP-ribose) polymerases). NAD+ peptides are being studied for their ability to enhance DNA repair mechanisms, particularly in response to oxidative stress or UV damage.
    • Clinical: Clinical applications focus on NAD+ peptides as potential treatments for conditions resulting from DNA damage, such as cancers or inherited disorders involving defects in DNA repair (e.g., xeroderma pigmentosum).

    7. Skeletal Muscle Function and Recovery

    • Preclinical: NAD+ peptides have been shown to improve mitochondrial function and muscle regeneration in animal models. Studies focus on their ability to enhance muscle strength, endurance, and recovery, particularly after exercise or injury.
    • Clinical: Clinical trials aim to evaluate the efficacy of NAD+ peptides in treating conditions such as sarcopenia (age-related muscle loss), muscle wasting in chronic diseases, and improving recovery in athletes or individuals with muscle injuries.

    8. Inflammation and Immune System Modulation

    • Preclinical: NAD+ peptides are being explored for their effects on inflammation and immune system regulation. Studies suggest that NAD+ can modulate immune responses and reduce chronic inflammation, which is a key factor in many diseases, including autoimmune disorders.
    • Clinical: Clinical studies may investigate NAD+ peptides for their potential to treat inflammatory diseases like rheumatoid arthritis, inflammatory bowel disease (IBD), and systemic inflammatory response syndrome (SIRS).

    9. Liver Health and Detoxification

    • Preclinical: NAD+ peptides may enhance liver function by boosting mitochondrial health, promoting detoxification processes, and reducing liver fibrosis or damage caused by metabolic diseases or alcohol consumption.
    • Clinical: Clinical trials are exploring NAD+ peptides as potential treatments for liver diseases, including non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, and cirrhosis.

    10. Autophagy and Cellular Homeostasis

    • Preclinical: NAD+ peptides influence autophagy, a process that helps cells remove damaged organelles and proteins. Preclinical research investigates how NAD+ modulation can support autophagy, improving cellular health and reducing the accumulation of damaged cellular components.
    • Clinical: Clinical studies are examining whether NAD+ peptides can promote autophagy in diseases where cellular homeostasis is compromised, such as neurodegenerative diseases, metabolic diseases, and certain types of cancers.

    Overall, NAD+ peptides are a promising area of research due to their broad impact on health, aging, and disease. However, much of the current evidence is still in preclinical or early clinical stages, and further studies are needed to confirm their safety, efficacy, and long-term effects in human populations.

    Product Specifications

    Please read our Terms and Conditions before purchasing any product from this website.
    Attribute NameAttribute Description
    1SemaglutideCAS #910463-68-2
    1PT-141CAS #1607799-13-2
    1SNAP-8SynonymsSCHEMBL20154760 BCP12742 SNAP-8(Acetyl Glutamyl Heptapeptide-3) Acetyl GlutaMyl Heptapeptide-3;Acetyl GlutaMyl Octapeptide-3;Acetyl Octapeptide-3;Acetyl Octapetpide-3;Acetyl Octapeptide-8;Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH
    1RetatrutideCAS #2381089-83-2
    2SemaglutideVial SpecsClear glass medicine vial. May differ slightly from product image.
    2PT-141Vial SpecsClear glass medicine vial. May differ slightly from product image.
    2SNAP-8Vial SpecsClear glass medicine vial. May differ slightly from product image.
    2RetatrutideVial SpecsClear glass medicine vial. May differ slightly from product image.
    3SemaglutideProduct ColorWhite lyophilized powder
    3PT-141Product ColorWhite lyophilized powder
    3SNAP-8Product ColorWhite lyophilized powder
    3RetatrutideProduct ColorWhite lyophilized powder
    3TesamorelinProduct ColorWhite lyophilized powder
    4SemaglutidePubChem CID56843331
    4PT-141PubChem CID9941379
    4SNAP-8PubChem CID86080331
    4RetatrutidePubChem CID474492335
    4TesamorelinPubChem CID146681838
    5SemaglutideMolecular Weight4113.64 g/mol
    5PT-141Molecular Weight1025.2 g/mol
    5SNAP-8Molecular Weight1075.2 g/mol
    5RetatrutideMolecular Weight4731.34 g/mol
    5TesamorelinMolecular Weight5136 g/mol
    6SemaglutideMolecular FormulaC187H291N45059
    6PT-141Molecular FormulaC50H68N14O10
    6RetatrutideMolecular FormulaC221H342N46O68
    6TesamorelinMolecular FormulaC221H366N72O67S
    7SemaglutideStorage (Shelf Life)For up to 2 years at 39 degrees fahrenheit and 3 years at -4 degree fahrenheit
    7PT-141Storage (Shelf Life)For up to 2 years at 39 degrees fahrenheit and 3 years at -4 degree fahrenheit
    7RetatrutideStorage (Shelf Life)For up to 2 years at 39 degrees fahrenheit and 3 years at -4 degree fahrenheit
    7SNAP-8Storage (Shelf Life)For up to 2 years at 39 degrees fahrenheit and 3 years at -4 degree fahrenheit
    9TesamorelinChemical Referencehttps://pubchem.ncbi.nlm.nih.gov/compound/146681838
    9SemaglutideChemical Referencehttps://pubchem.ncbi.nlm.nih.gov/compound/5684333
    9SNAP-8Chemical Referencehttps://pubchem.ncbi.nlm.nih.gov/compound/SNAP-8_Acetyl-Glutamyl-Heptapeptide-3
    9PT-141Chemical Referencehttps://pubchem.ncbi.nlm.nih.gov/compound/Bremelanotide
    9RetatrutideChemical Referencehttps://pubchem.ncbi.nlm.nih.gov/substance/474492335
    1GHK-Cu-RawCAS #49557-75-7
    1TesamorelinCAS #218949-48-5
    2GHK-Cu-RawVial SpecsClear glass medicine vial. May differ slightly from product image.
    2TesamorelinVial SpecsClear glass medicine vial. May differ slightly from product image.
    3GHK-Cu-RawProduct ColorWhite powder
    4GHK-Cu-RawPubChem CID73587
    5GHK-Cu-RawMolecular Weight340.38 g/mol
    6GHK-Cu-RawMolecular FormulaC14H24N6O4
    7GHK-Cu-RawStorageStore in a cool dark place. For best preservation, store at 4°C or colder.
    9GHK-Cu-RawChemical Referencehttps://pubchem.ncbi.nlm.nih.gov/compound/73587
    1Semaglutide-RawCAS #910463-68-2
    2Semaglutide-RawVial SpecsClear glass medicine vial. May differ slightly from product image.
    3Semaglutide-RawProduct ColorWhite powder
    4Semaglutide-RawPubChem CID56843331
    5Semaglutide-RawMolecular Weight4113.64 g/mol
    6Semaglutide-RawMolecular FormulaC187H291N45059
    7Semaglutide-RawStorageStore in a cool dark place. For best preservation, store at 4°C or colder.
    9Semaglutide-RawChemical Referencehttps://pubchem.ncbi.nlm.nih.gov/compound/5684333
    1BPC-157-RawCAS #137525-51-0
    2BPC-157-RawVial SpecsClear glass medicine vial. May differ slightly from product image.
    3BPC-157-RawProduct ColorWhite powder
    4BPC-157-RawPubChem CID9941957
    5BPC-157-RawMolecular Weight1419.5 g/mol
    6BPC-157-RawMolecular FormulaC62H98N16O22
    7BPC-157-RawStorageStore in a cool dark place. For best preservation, store at 4°C or colder.
    9BPC-157-RawChemical Referencehttps://pubchem.ncbi.nlm.nih.gov/compound/9941957
    1Tirzepatide-RawCAS #2023788-19-2
    2Tirzepatide-RawVial SpecsClear glass medicine vial. May differ slightly from product image.
    3Tirzepatide-RawProduct ColorWhite powder
    4Tirzepatide-RawPubChem CIDNot available because this is not a discrete structure.
    5Tirzepatide-RawMolecular WeightNot available
    6Tirzepatide-RawMolecular FormulaC187H291N45059
    7Tirzepatide-RawStorage (Shelf Life)Store in a cool dark place. For best preservation, store at 4°C or colder.
    9Tirzepatide-RawChemical Referencehttps://pubchem.ncbi.nlm.nih.gov/compound/Tirzepatide
    1BPC-157CAS #137525-51-0
    2BPC-157Vial SpecsClear glass medicine vial. May differ slightly from product image.
    3BPC-157Product ColorWhite lyophilized powder
    4BPC-157PubChem CID9941957
    5BPC-157Molecular Weight1419.5 g/mol
    6BPC-157Molecular FormulaC62H98N16O22
    7BPC-157Storage (Shelf Life)For up to 2 years at 39 degrees fahrenheit and 3 years at -4 degree fahrenheit
    9BPC-157Chemical Referencehttps://pubchem.ncbi.nlm.nih.gov/compound/9941957
    1CJC-1295-NDCAS #863288-34-0
    2CJC-1295-NDVial SpecsClear glass medicine vial. May differ slightly from product image.
    3CJC-1295-NDProduct ColorWhite lyophilized powder
    4CJC-1295-NDPubChem CID56841945
    5CJC-1295-NDMolecular Weight3367.9 g/mol
    6CJC-1295-NDMolecular FormulaC152H252N44O42
    7CJC-1295-NDStorageStore in a cool, dark place. For best preservation, store them under refrigeration at 4°C or colder.
    9CJC-1295-NDChemical Referencehttps://pubchem.ncbi.nlm.nih.gov/compound/56841945
    1EpithalonCAS #307297-39-8
    2EpithalonVial SpecsClear glass medicine vial. May differ slightly from product image.
    3EpithalonProduct ColorWhite lyophilized powder
    4EpithalonPubChem CID219042
    5EpithalonMolecular Weight390.35 g/mol
    6EpithalonMolecular FormulaC14H22N4O9
    7EpithalonStorage (Shelf Life)For up to 2 years at 39 degrees fahrenheit and 3 years at -4 degree fahrenheit
    9EpithalonChemical Referencehttps://pubchem.ncbi.nlm.nih.gov/compound/219042
    1GHK-CuCAS #49557-75-7
    2GHK-CuVial SpecsClear glass medicine vial. May differ slightly from product image.
    3GHK-CuProduct ColorBlue powder
    4GHK-CuPubChem CID73587
    5GHK-CuMolecular Weight340.38 g/mol
    6GHK-CuMolecular FormulaC14H24N6O4
    7GHK-CuStorage (Shelf Life)For up to 2 years at 39 degrees fahrenheit and 3 years at -4 degree fahrenheit
    9GHK-CuChemical Referencehttps://pubchem.ncbi.nlm.nih.gov/compound/73587
    1IpamorelinCAS #170851-70-4
    2IpamorelinVial SpecsClear glass medicine vial. May differ slightly from product image.
    3IpamorelinProduct ColorWhite lyophilized powder
    4IpamorelinPubChem CID9831659
    5IpamorelinMolecular Weight711.9 g/mol
    6IpamorelinMolecular FormulaC38H49N9O5
    7IpamorelinStorage (Shelf Life)For up to 2 years at 39 degrees fahrenheit and 3 years at -4 degree fahrenheit
    9IpamorelinChemical Referencehttps://pubchem.ncbi.nlm.nih.gov/compound/9831659
    1Mots-CCAS #1627580-64-6
    2Mots-CVial SpecsClear glass medicine vial. May differ slightly from product image.
    3Mots-CProduct ColorWhite lyophilized powder
    4Mots-CPubChem CID146675088
    5Mots-CMolecular Weight2174.6 g/mol
    6Mots-CMolecular FormulaC101H152N28O22S2
    7Mots-CStorage (Shelf Life)For up to 2 years at 39 degrees fahrenheit and 3 years at -4 degree fahrenheit
    9Mots-CChemical Referencehttps://pubchem.ncbi.nlm.nih.gov/compound/146675088
    1Melanotan-MT2CAS #121062-08-6
    2Melanotan-MT2Vial SpecsClear glass medicine vial. May differ slightly from product image.
    3Melanotan-MT2Product ColorWhite lyophilized powder
    4Melanotan-MT2PubChem CID92432
    5Melanotan-MT2Molecular Weight1024.2 g/mol
    6Melanotan-MT2Molecular FormulaC50H69N15O9
    7Melanotan-MT2Storage (Shelf Life)For up to 2 years at 39 degrees fahrenheit and 3 years at -4 degree fahrenheit
    9Melanotan-MT2Chemical Referencehttps://pubchem.ncbi.nlm.nih.gov/compound/92432
    1TB-500CAS #77591-33-4
    2TB-500Vial SpecsClear glass medicine vial. May differ slightly from product image.
    3TB-500Product ColorWhite lyophilized powder
    4TB-500PubChem CID16132341
    5TB-500Molecular Weight4963 g/mol
    6TB-500Molecular FormulaC212H350N56O78S
    7TB-500Storage (Shelf Life)For up to 2 years at 39 degrees fahrenheit and 3 years at -4 degree fahrenheit
    9TB-500Chemical Referencehttps://pubchem.ncbi.nlm.nih.gov/compound/16132341
    1Thymosin A1CAS #62304-98-7
    2Thymosin A1Vial SpecsClear glass medicine vial. May differ slightly from product image.
    3Thymosin A1Product ColorWhite lyophilized powder
    4Thymosin A1PubChem CID16130571
    5Thymosin A1Molecular Weight3108.3 g/mol
    6Thymosin A1Molecular FormulaC129H215N33O55
    7Thymosin A1Storage (Shelf Life)For up to 2 years at 39 degrees fahrenheit and 3 years at -4 degree fahrenheit
    9Thymosin A1Chemical Referencehttps://pubchem.ncbi.nlm.nih.gov/compound/Thymalfasin
    1TirzepatideCAS #2023788-19-2
    2TirzepatideVial SpecsClear glass medicine vial. May differ slightly from product image.
    3TirzepatideProduct ColorWhite lyophilized powder
    4TirzepatidePubChem CIDNot available because this is not a discrete structure.
    5TirzepatideMolecular WeightNot available
    6TirzepatideMolecular FormulaC187H291N45059
    7TirzepatideStorage (Shelf Life)For up to 2 years at 39 degrees fahrenheit and 3 years at -4 degree fahrenheit
    9TirzepatideChemical Referencehttps://pubchem.ncbi.nlm.nih.gov/compound/Tirzepatide

    Reference Articles

    *All information found here or in our Reference Library is for educational purposes only. Citations are not a source, study claim, or advertisement for products sold on this website.
    SourceSubjectReference TitleCitationMore Info
    Thymosin Alpha-1National Library of Medicine (NIH)CancerA Reappraisal of Thymosin Alpha1 in Cancer TherapyCostantini C, Bellet MM, Pariano M, Renga G, Stincardini C, Goldstein AL, Garaci E, Romani L. A Reappraisal of Thymosin Alpha1 in Cancer Therapy. Front Oncol. 2019 Sep 6;9:873. doi: 10.3389/fonc.2019.00873. PMID: 31555601; PMCID: PMC6742685.View
    Thymosin Alpha-1National Library of Medicine (NIH)Hepatitis BThymosin alpha-1 treatment in chronic hepatitis BWu X, Jia J, You H. Thymosin alpha-1 treatment in chronic hepatitis B. Expert Opin Biol Ther. 2015;15 Suppl 1:S129-32. doi: 10.1517/14712598.2015.1007948. Epub 2015 Feb 1. PMID: 25640173.View
    Thymosin Alpha-1National Library of Medicine (NIH)Cystic FibrosisThymosin alpha 1 exerts beneficial extrapulmonary effects in cystic fibrosisBellet MM, Borghi M, Pariano M, Renga G, Stincardini C, D’Onofrio F, Brancorsini S, Garaci E, Costantini C, Romani L. Thymosin alpha 1 exerts beneficial extrapulmonary effects in cystic fibrosis. Eur J Med Chem. 2021 Jan 1;209:112921. doi: 10.1016/j.ejmech.2020.112921. Epub 2020 Oct 9. PMID: 33071052.View
    Thymosin Alpha-1National Library of Medicine (NIH)Infectious DiseaseThymosin α1 and Its Role in Viral Infectious Diseases: The Mechanism and Clinical ApplicationTao N, Xu X, Ying Y, Hu S, Sun Q, Lv G, Gao J. Thymosin α1 and Its Role in Viral Infectious Diseases: The Mechanism and Clinical Application. Molecules. 2023 Apr 17;28(8):3539. doi: 10.3390/molecules28083539. PMID: 37110771; PMCID: PMC10144173.View
    Thymosin Alpha-1National Library of Medicine (NIH)Respiratory (COPD)Thymosin α1 plus routine treatment inhibit inflammatory reaction and improve the quality of life in AECOPD patientsJia Z, Feng Z, Tian R, Wang Q, Wang L. Thymosin α1 plus routine treatment inhibit inflammatory reaction and improve the quality of life in AECOPD patients. Immunopharmacol Immunotoxicol. 2015;37(4):388-92. doi: 10.3109/08923973.2015.1069837. PMID: 26250523.View
    Thymosin Alpha-1ACS OmegaCancer (Lung)Modified Thymosin Alpha 1 Distributes and Inhibits the Growth of Lung Cancer in VivoRenhao Peng, Caoying Xu, Heng Zheng, and Xingzhen Lao ACS Omega 2020 5 (18), 10374-10381 DOI: 10.1021/acsomega.0c00220View
    SemaglutideNational Library of Medicine (NIH)DiabetesSemaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetesMahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord. 2022 Jun;23(3):521-539. doi: 10.1007/s11154-021-09699-1. Epub 2022 Jan 7. PMID: 34993760; PMCID: PMC8736331.View
    RetatrutideNational Library of Medicine (NIH)DiabetesRetatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USARosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023 Aug 12;402(10401):529-544. doi: 10.1016/S0140-6736(23)01053-X. Epub 2023 Jun 26. PMID: 37385280.View
    SemaglutideNational Library of Medicine (NIH)Weight LossWeight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or ObesityGhusn W, De la Rosa A, Sacoto D, Cifuentes L, Campos A, Feris F, Hurtado MD, Acosta A. Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA Netw Open. 2022 Sep 1;5(9):e2231982. doi: 10.1001/jamanetworkopen.2022.31982. PMID: 36121652; PMCID: PMC9486455.View
    RetatrutideNational Library of Medicine (NIH)Weight LossUnleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondenceNaeem M, Imran L, Banatwala UESS. Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence. Health Sci Rep. 2024 Feb 5;7(2):e1864. doi: 10.1002/hsr2.1864. PMID: 38323122; PMCID: PMC10844714.View
    RetatrutideNational Library of Medicine (NIH)AddictionThe role of glucagon‐like peptide 1 (GLP‐1) in addictive disordersKlausen MK, Thomsen M, Wortwein G, Fink-Jensen A. The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. Br J Pharmacol. 2022 Feb;179(4):625-641. doi: 10.1111/bph.15677. PMID: 34532853; PMCID: PMC8820218.View
    SemaglutideNational Library of Medicine (NIH)Liver (NAFLD)Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesityNewsome P, Francque S, Harrison S, Ratziu V, Van Gaal L, Calanna S, Hansen M, Linder M, Sanyal A. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. Aliment Pharmacol Ther. 2019 Jul;50(2):193-203. doi: 10.1111/apt.15316. Epub 2019 Jun 10. PMID: 31246368; PMCID: PMC6617813.View
    BPC-157National Library of Medicine (NIH)Healing (Tendon)The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migrationChang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011 Mar;110(3):774-80. doi: 10.1152/japplphysiol.00945.2010. Epub 2010 Oct 28. PMID: 21030672.View
    BPC-157National Library of Medicine (NIH)Arthritis (Knee Pain)Intra-Articular Injection of BPC 157 for Multiple Types of Knee PainLee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021 Jul;27(4):8-13. PMID: 34324435.View
    BPC-157National Library of Medicine (NIH)Wound HealingStable Gastric Pentadecapeptide BPC 157 and Wound HealingSeiwerth S, Milavic M, Vukojevic J, Gojkovic S, Krezic I, Vuletic LB, Pavlov KH, Petrovic A, Sikiric S, Vranes H, Prtoric A, Zizek H, Durasin T, Dobric I, Staresinic M, Strbe S, Knezevic M, Sola M, Kokot A, Sever M, Lovric E, Skrtic A, Blagaic AB, Sikiric P. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021 Jun 29;12:627533. doi: 10.3389/fphar.2021.627533. PMID: 34267654; PMCID: PMC8275860.View
    GHK-CuNational Library of Medicine (NIH)Multiple (Anti-aging, Healing, Inflammation, Hair Growth)Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene DataPickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018 Jul 7;19(7):1987. doi: 10.3390/ijms19071987. PMID: 29986520; PMCID: PMC6073405.View
    GHK-CuNational Library of Medicine (NIH)Hair RegenerationThermodynamically stable ionic liquid microemulsions pioneer pathways for topical delivery and peptide applicationLiu T, Liu Y, Zhao X, Zhang L, Wang W, Bai D, Liao Y, Wang Z, Wang M, Zhang J. Thermodynamically stable ionic liquid microemulsions pioneer pathways for topical delivery and peptide application. Bioact Mater. 2023 Nov 1;32:502-513. doi: 10.1016/j.bioactmat.2023.10.002. PMID: 38026438; PMCID: PMC10643103.View
    CJC-1295-NDNational Library of Medicine (NIH)Bone Density (Osteoporosis)Growth hormone increases bone mineral content in postmenopausal osteoporosis: a randomized placebo-controlled trialLandin-Wilhelmsen K, Nilsson A, Bosaeus I, Bengtsson BA. Growth hormone increases bone mineral content in postmenopausal osteoporosis: a randomized placebo-controlled trial. J Bone Miner Res. 2003 Mar;18(3):393-405. doi: 10.1359/jbmr.2003.18.3.393. PMID: 12619921.View
    TB-500National Library of Medicine (NIH)Wound HealingThymosin beta4 accelerates wound healingMalinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, Kleinman HK. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999 Sep;113(3):364-8. doi: 10.1046/j.1523-1747.1999.00708.x. PMID: 10469335.View
    TB-500National Library of Medicine (NIH)Hair GrowthThymosin beta 4 induces hair growth via stem cell migration and differentiationPhilp D, St-Surin S, Cha HJ, Moon HS, Kleinman HK, Elkin M. Thymosin beta 4 induces hair growth via stem cell migration and differentiation. Ann N Y Acad Sci. 2007 Sep;1112:95-103. doi: 10.1196/annals.1415.009. PMID: 17947589.View
    TB-500National Library of Medicine (NIH)Anti-InflammatoryThymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoidsYoung JD, Lawrence AJ, MacLean AG, Leung BP, McInnes IB, Canas B, Pappin DJ, Stevenson RD. Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids. Nat Med. 1999 Dec;5(12):1424-7. doi: 10.1038/71002. PMID: 10581087.View
    TesamorelinNational Library of Medicine (NIH)Visceral Fat, HIVVisceral Fat Reduction with Tesamorelin Is Associated with Improved Liver Enzymes in HIVFourman LT, Czerwonka N, Feldpausch MN, Weiss J, Mamputu JC, Falutz J, Morin J, Marsolais C, Stanley TL, Grinspoon SK. Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. AIDS. 2017 Oct 23;31(16):2253-2259. doi: 10.1097/QAD.0000000000001614. PMID: 28832410; PMCID: PMC5633509.View
    TesamorelinNational Library of Medicine (NIH)NAFLDEffects of Tesamorelin on Nonalcoholic Fatty Liver Disease in HIV: A Randomized, Double-Blind, Multicenter TrialStanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, Aepfelbacher J, Buckless C, Tsao A, Kellogg A, Branch K, Lee H, Liu CY, Corey KE, Chung RT, Torriani M, Kleiner DE, Hadigan CM, Grinspoon SK. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019 Dec;6(12):e821-e830. doi: 10.1016/S2352-3018(19)30338-8. Epub 2019 Oct 11. PMID: 31611038; PMCID: PMC6981288.View
    TesamorelinNational Library of Medicine (NIH)Scarpenia, HIVThe Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIVAdrian S, Scherzinger A, Sanyal A, Lake JE, Falutz J, Dubé MP, Stanley T, Grinspoon S, Mamputu JC, Marsolais C, Brown TT, Erlandson KM. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging. 2019;8(3):154-159. doi: 10.14283/jfa.2018.45. PMID: 31237318; PMCID: PMC6766405.View
    TB-500National Library of Medicine (NIH)Regenerative (Healing)The regenerative peptide thymosin ?4 accelerates the rate of dermal healing in preclinical animal models and in patientsTreadwell T, Kleinman HK, Crockford D, Hardy MA, Guarnera GT, Goldstein AL. The regenerative peptide thymosin ?4 accelerates the rate of dermal healing in preclinical animal models and in patients. Ann N Y Acad Sci. 2012 Oct;1270:37-44. doi: 10.1111/j.1749-6632.2012.06717.x. PMID: 23050815.View
    TB-500National Library of Medicine (NIH)Performance EnhancementThe potential use and abuse of thymosin ?-4 in sport and exercise scienceDavison G, Brown S. The potential use and abuse of thymosin ?-4 in sport and exercise science. J Sports Sci. 2013;31(9):917-8. doi: 10.1080/02640414.2013.771958. Epub 2013 Feb 20. PMID: 23421910.View
    TB-500National Library of Medicine (NIH)Traumatic Brain InjuryNeuroprotective and neurorestorative effects of Thymosin beta 4 treatment following experimental traumatic brain injuryXiong Y, Mahmood A, Meng Y, Zhang Y, Zhang ZG, Morris DC, Chopp M. Neuroprotective and neurorestorative effects of thymosin ?4 treatment following experimental traumatic brain injury. Ann N Y Acad Sci. 2012 Oct;1270:51-8. doi: 10.1111/j.1749-6632.2012.06683.x. PMID: 23050817; PMCID: PMC3547647.View
    TB-500National Library of Medicine (NIH)Regenerative (Cardiac)Thymosin beta4 and cardiac repairShrivastava S, Srivastava D, Olson EN, DiMaio JM, Bock-Marquette I. Thymosin beta4 and cardiac repair. Ann N Y Acad Sci. 2010 Apr;1194:87-96. doi: 10.1111/j.1749-6632.2010.05468.x. PMID: 20536454.View
    TB-500National Library of Medicine (NIH)Liver (NAFLD)Potential role of thymosin beta 4 in the treatment of nonalcoholic fatty liver diseaseJiang Y, Han T, Zhang ZG, Li M, Qi FX, Zhang Y, Ji YL. Potential role of thymosin beta 4 in the treatment of nonalcoholic fatty liver disease. Chronic Dis Transl Med. 2017 Jul 8;3(3):165-168. doi: 10.1016/j.cdtm.2017.06.003. PMID: 29063072; PMCID: PMC5643779.View
    EpithalonNational Library of Medicine (NIH)Anti-AgingEffect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR miceAnisimov VN, Khavinson VKh, Popovich IG, Zabezhinski MA, Alimova IN, Rosenfeld SV, Zavarzina NY, Semenchenko AV, Yashin AI. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193-202. doi: 10.1023/a:1025114230714. PMID: 14501183.View
    EpithalonNational Library of Medicine (NIH)Cancer (Tumors)Effect of the synthetic pineal peptide epitalon on spontaneous carcinogenesis in female C3H/He miceKossoy G, Anisimov VN, Ben-Hur H, Kossoy N, Zusman I. Effect of the synthetic pineal peptide epitalon on spontaneous carcinogenesis in female C3H/He mice. In Vivo. 2006 Mar-Apr;20(2):253-7. PMID: 16634527.View
    EpithalonAlzheimers Drug Discovery FoundationCognitive, Aging, CancerEpithalamin/EpithalonAlzheimer’s Drug Discovery Foundation. (n.d.). Cognitive vitality reports. https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Epithalamin-and-Epithalon-Cognitive-Vitality-For-Researchers.pdfView
    EpithalonNational Library of Medicine (NIH)Neuroendocrine Regulation (Melatonin Synthesis – Improved Sleep)Synthetic tetrapeptide epitalon restores disturbed neuroendocrine regulation in senescent monkeysKhavinson V, Goncharova N, Lapin B. Synthetic tetrapeptide epitalon restores disturbed neuroendocrine regulation in senescent monkeys. Neuro Endocrinol Lett. 2001 Aug;22(4):251-4. PMID: 11524632.View
    IpamorelinNational Library of Medicine (NIH)Growth HormoneIpamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in ratsJohansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999 Apr;9(2):106-13. doi: 10.1054/ghir.1999.9998. PMID: 10373343.View
    IpamorelinNational Library of Medicine (NIH)Body Composition (Hypogonadal)Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal malesSinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020 Mar;9(Suppl 2):S149-S159. doi: 10.21037/tau.2019.11.30. PMID: 32257855; PMCID: PMC7108996.View
    IpamorelinNational Library of Medicine (NIH)Gastric Emptying (Dysmotility)Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileusGreenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. J Exp Pharmacol. 2012 Oct 19;4:149-55. doi: 10.2147/JEP.S35396. PMID: 27186127; PMCID: PMC4863553.View
    BPC-157National Library of Medicine (NIH)Hormone RegulationPentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblastsChang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014 Nov 19;19(11):19066-77. doi: 10.3390/molecules191119066. PMID: 25415472; PMCID: PMC6271067.View
    BPC-157National Library of Medicine (NIH)Anti-InflammtoryAntiinflammatory effect of BPC 157 on experimental periodontitis in ratsKeremi B, Lohinai Z, Komora P, Duhaj S, Borsi K, Jobbagy-Ovari G, Kallo K, Szekely AD, Fazekas A, Dobo-Nagy C, Sikiric P, Varga G. Antiinflammatory effect of BPC 157 on experimental periodontitis in rats. J Physiol Pharmacol. 2009 Dec;60 Suppl 7:115-22. PMID: 20388954.View
    BPC-157National Library of Medicine (NIH)Brain-Gut (GI – Gastrointestinal)Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical ImplicationsSikiric P, Seiwerth S, Rucman R, Kolenc D, Vuletic LB, Drmic D, Grgic T, Strbe S, Zukanovic G, Crvenkovic D, Madzarac G, Rukavina I, Sucic M, Baric M, Starcevic N, Krstonijevic Z, Bencic ML, Filipcic I, Rokotov DS, Vlainic J. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. 2016;14(8):857-865. doi: 10.2174/1570159×13666160502153022. PMID: 27138887; PMCID: PMC5333585.View
    BPC-157National Library of Medicine (NIH)Central Nervous System (Brain-Gut Axis)Pentadecapeptide BPC 157 and the central nervous systemVukojevic J, Milavić M, Perović D, Ilić S, Čilić AZ, Đuran N, Štrbe S, Zoričić Z, Filipčić I, Brečić P, Seiverth S, Sikirić P. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022 Mar;17(3):482-487. doi: 10.4103/1673-5374.320969. PMID: 34380875; PMCID: PMC8504390.View
    GHK-CuNational Library of Medicine (NIH)Skin Regeneration (Tissue Repair)GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin RegenerationPickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. doi: 10.1155/2015/648108. Epub 2015 Jul 7. PMID: 26236730; PMCID: PMC4508379.View
    GHK-CuNational Library of Medicine (NIH)Anti-AgingThe potential of GHK as an anti-aging peptideDou Y, Lee A, Zhu L, Morton J, Ladiges W. The potential of GHK as an anti-aging peptide. Aging Pathobiol Ther. 2020 Mar 27;2(1):58-61. doi: 10.31491/apt.2020.03.014. PMID: 35083444; PMCID: PMC8789089.View
    GHK-CuNational Library of Medicine (NIH)Hair GrowthThe effect of tripeptide-copper complex on human hair growth in vitroPyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007 Jul;30(7):834-9. doi: 10.1007/BF02978833. PMID: 17703734.View
    CJC-1295-NDNational Library of Medicine (NIH)Growth HormoneAn immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasmaTimms M, Ganio K, Forbes G, Bailey S, Steel R. An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma. Drug Test Anal. 2019 Jun;11(6):804-812. doi: 10.1002/dta.2554. Epub 2018 Dec 25. PMID: 30489688.View
    CJC-1295-NDNational Library of Medicine (NIH)Enhanced Muscle, Fat Loss, Improved SleepNetnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and PotionsVan Hout MC, Hearne E. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Subst Use Misuse. 2016 Jan 2;51(1):73-84. doi: 10.3109/10826084.2015.1082595. Epub 2016 Jan 15. PMID: 26771670.View
    EpithalonNational Library of Medicine (NIH)Gene Expression (DNA Regulation)AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic MechanismKhavinson V, Diomede F, Mironova E, Linkova N, Trofimova S, Trubiani O, Caputi S, Sinjari B. AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism. Molecules. 2020 Jan 30;25(3):609. doi: 10.3390/molecules25030609. PMID: 32019204; PMCID: PMC7037223.View
    EpithalonNational Library of Medicine (NIH)Cardiovascular, Endocrine, Immune & Nervous SystemsGeroprotective effect of thymalin and epithalaminKhavinson VKh, Morozov VG. Geroprotektornaia éffektivnost’ timalina i épitalamina [Geroprotective effect of thymalin and epithalamin]. Adv Gerontol. 2002;10:74-84. Russian. PMID: 12577695.View
    IpamorelinNational Library of Medicine (NIH)Bone Mineral Content (Bone Density)The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female ratsSvensson J, Lall S, Dickson SL, Bengtsson BA, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson JO. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000 Jun;165(3):569-77. doi: 10.1677/joe.0.1650569. PMID: 10828840.View
    IpamorelinNational Library of Medicine (NIH)MetabolismMetabolism of growth hormone releasing peptidesThomas A, Delahaut P, Krug O, Schänzer W, Thevis M. Metabolism of growth hormone releasing peptides. Anal Chem. 2012 Dec 4;84(23):10252-9. doi: 10.1021/ac302034w. Epub 2012 Nov 13. PMID: 23101768.View
    Melanotan-MT2National Library of Medicine (NIH)MelaninEffect of MELANOTAN, [Nle(4), D-Phe(7)]-alpha-MSH, on melanin synthesis in humans with MC1R variant allelesFitzgerald LM, Fryer JL, Dwyer T, Humphrey SM. Effect of MELANOTAN, [Nle(4), D-Phe(7)]-alpha-MSH, on melanin synthesis in humans with MC1R variant alleles. Peptides. 2006 Feb;27(2):388-94. doi: 10.1016/j.peptides.2004.12.038. Epub 2005 Nov 15. PMID: 16293341.View
    Melanotan-MT2National Library of Medicine (NIH)Appetite and Body MassActivation of the central melanocortin system chronically reduces body mass without the necessity of long-term caloric restrictionActivation of the central melanocortin system chronically reduces body mass without the necessity of long-term caloric restrictionView
    Melanotan-MT2National Library of Medicine (NIH)AddictionMelatonin in drug addiction and addiction management: Exploring an evolving multidimensional relationshipOnaolapo OJ, Onaolapo AY. Melatonin in drug addiction and addiction management: Exploring an evolving multidimensional relationship. World J Psychiatry. 2018 Jun 28;8(2):64-74. doi: 10.5498/wjp.v8.i2.64. PMID: 29988891; PMCID: PMC6033744.View
    Melanotan-MT2National Library of Medicine (NIH)Erectile Dysfunction (ED)Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan IIWessells H, Levine N, Hadley ME, Dorr R, Hruby V. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000 Oct;12 Suppl 4:S74-9. doi: 10.1038/sj.ijir.3900582. PMID: 11035391.View
    Melanotan-MT2National Library of Medicine (NIH)Binge Drinking (Addiction)The protective effects of the melanocortin receptor (MCR) agonist, melanotan-II (MTII), against binge-like ethanol drinking are facilitated by deletion of the MC3 receptor in miceOlney JJ, Sprow GM, Navarro M, Thiele TE. The protective effects of the melanocortin receptor (MCR) agonist, melanotan-II (MTII), against binge-like ethanol drinking are facilitated by deletion of the MC3 receptor in mice. Neuropeptides. 2014 Feb;48(1):47-51. doi: 10.1016/j.npep.2013.11.001. Epub 2013 Nov 15. PMID: 24290566; PMCID: PMC3946855.View
    Melanotan-MT2National Library of Medicine (NIH)AutismMelatonin: From Pharmacokinetics to Clinical Use in Autism Spectrum DisorderLalanne S, Fougerou-Leurent C, Anderson GM, Schroder CM, Nir T, Chokron S, Delorme R, Claustrat B, Bellissant E, Kermarrec S, Franco P, Denis L, Tordjman S. Melatonin: From Pharmacokinetics to Clinical Use in Autism Spectrum Disorder. Int J Mol Sci. 2021 Feb 2;22(3):1490. doi: 10.3390/ijms22031490. PMID: 33540815; PMCID: PMC7867370.View
    Melanotan-MT2National Library of Medicine (NIH)Sexual LibidoMelatonin enhances sexual behavior in the male ratBrotto LA, Gorzalka BB. Melatonin enhances sexual behavior in the male rat. Physiol Behav. 2000 Feb;68(4):483-6. doi: 10.1016/s0031-9384(99)00204-8. PMID: 10713287.View
    Melanotan-MT2National Library of Medicine (NIH)Childhood AutismMelatonin and Comorbidities in Children with Autism Spectrum DisorderGagnon K, Godbout R. Melatonin and Comorbidities in Children with Autism Spectrum Disorder. Curr Dev Disord Rep. 2018;5(3):197-206. doi: 10.1007/s40474-018-0147-0. Epub 2018 Aug 9. PMID: 30148039; PMCID: PMC6096870.View
    Mots-CNational Library of Medicine (NIH)Metabolic StressMitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and agingWan W, Zhang L, Lin Y, Rao X, Wang X, Hua F, Ying J. Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. J Transl Med. 2023 Jan 20;21(1):36. doi: 10.1186/s12967-023-03885-2. PMID: 36670507; PMCID: PMC9854231.View
    Mots-CNational Library of Medicine (NIH)Diabetes (Insulin Resistance)Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related DiseasesKong BS, Lee C, Cho YM. Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases. Diabetes Metab J. 2023 May;47(3):315-324. doi: 10.4093/dmj.2022.0333. Epub 2023 Feb 24. PMID: 36824008; PMCID: PMC10244198.View
    Mots-CNational Library of Medicine (NIH)OsteoporisMOTS-c improves osteoporosis by promoting osteogenic differentiation of bone marrow mesenchymal stem cells via TGF-β/Smad pathwayHu BT, Chen WZ. MOTS-c improves osteoporosis by promoting osteogenic differentiation of bone marrow mesenchymal stem cells via TGF-β/Smad pathway. Eur Rev Med Pharmacol Sci. 2018 Nov;22(21):7156-7163. doi: 10.26355/eurrev_201811_16247. PMID: 30468456.View
    Mots-CNational Library of Medicine (NIH)Mitochondrial EnergyMOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitationZheng Y, Wei Z, Wang T. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Front Endocrinol (Lausanne). 2023 Jan 25;14:1120533. doi: 10.3389/fendo.2023.1120533. PMID: 36761202; PMCID: PMC9905433.View
    Mots-CNational Library of Medicine (NIH)Metabolic Disorders, Obesity (Weight Loss)MOTS-c Functionally Prevents Metabolic DisordersGao Y, Wei X, Wei P, Lu H, Zhong L, Tan J, Liu H, Liu Z. MOTS-c Functionally Prevents Metabolic Disorders. Metabolites. 2023 Jan 13;13(1):125. doi: 10.3390/metabo13010125. PMID: 36677050; PMCID: PMC9866798.View
    SemaglutideNational Library of Medicine (NIH)Appetite, Weight LossEffects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesityBlundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, Hjerpsted JB. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017 Sep;19(9):1242-1251. doi: 10.1111/dom.12932. Epub 2017 May 5. PMID: 28266779; PMCID: PMC5573908.View
    SemaglutideNational Library of Medicine (NIH)Alzheimer’s DiseaseSemaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer’s disease via the GLP-1R/SIRT1/GLUT4 pathwayWang ZJ, Li XR, Chai SF, Li WR, Li S, Hou M, Li JL, Ye YC, Cai HY, Hölscher C, Wu MN. Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer’s disease via the GLP-1R/SIRT1/GLUT4 pathway. Neuropharmacology. 2023 Dec 1;240:109716. doi: 10.1016/j.neuropharm.2023.109716. Epub 2023 Sep 18. PMID: 37730113.View
    SemaglutideNational Library of Medicine (NIH)Alzheimer’s DiseaseHypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolismWang Y, Hu H, Liu X, Guo X. Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism. Front Pharmacol. 2023 Feb 23;14:1138499. doi: 10.3389/fphar.2023.1138499. PMID: 36909158; PMCID: PMC9995522.View
    SemaglutideNational Library of Medicine (NIH)Insulin Secretion, DiabetesEffects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trialKapitza C, Dahl K, Jacobsen JB, Axelsen MB, Flint A. Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. Diabetologia. 2017 Aug;60(8):1390-1399. doi: 10.1007/s00125-017-4289-0. Epub 2017 May 19. PMID: 28526920; PMCID: PMC5491562.View
    TirzepatideNational Library of Medicine (NIH)DiabetesTirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspectiveDe Block C, Bailey C, Wysham C, Hemmingway A, Allen SE, Peleshok J. Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective. Diabetes Obes Metab. 2023 Jan;25(1):3-17. doi: 10.1111/dom.14831. Epub 2022 Aug 31. PMID: 35929488; PMCID: PMC10087310.View
    TirzepatideNational Library of Medicine (NIH)Weight LossWeight loss efficiency and safety of tirzepatide: A Systematic reviewLin F, Yu B, Ling B, Lv G, Shang H, Zhao X, Jie X, Chen J, Li Y. Weight loss efficiency and safety of tirzepatide: A Systematic review. PLoS One. 2023 May 4;18(5):e0285197. doi: 10.1371/journal.pone.0285197. PMID: 37141329; PMCID: PMC10159347.View
    TirzepatideNational Library of Medicine (NIH)DigestionTirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trialsCai W, Zhang R, Yao Y, Wu Q, Zhang J. Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials. Front Public Health. 2024 Jan 31;12:1277113. doi: 10.3389/fpubh.2024.1277113. PMID: 38356942; PMCID: PMC10864442.View
    TirzepatideNational Library of Medicine (NIH)Appetite (Weight Loss)Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 DiabetesHeise T, DeVries JH, Urva S, Li J, Pratt EJ, Thomas MK, Mather KJ, Karanikas CA, Dunn J, Haupt A, Milicevic Z, Coskun T. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes Care. 2023 May 1;46(5):998-1004. doi: 10.2337/dc22-1710. PMID: 36857477; PMCID: PMC10154650.View
    TirzepatideNational Library of Medicine (NIH)Diabetes, Insulin Senstivity, ObesityTirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-ReviewTirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-ReviewView

    Product Notice

    • Consumer is responsible for understanding chemical safety and usage requirements for this product.
    • This product is for research and educational purposes only and is not intended to diagnose, cure, treat, or prevent any health condition or disease.
    • This product has not been approved by the FDA for human or animal consumption and should not be used as an alternative or generic form of any FDA approved drug sharing similar chemical properties.

     

    SKU: PEP-NAD+-500MG